Based primarily on our promising preclinical data, we have recently completed a phase 0, biomarker driven clinical trial of STAT3 decoy oligonucleotide in patients with resectable HNSCC [13]. The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.